3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
9
Neoplasms
5
Myelodysplastic Syndromes
4
Carcinoma, Non-Small-Cell Lung
4
Hematologic Neoplasms
3
Urinary Bladder Neoplasms
2
Recurrence
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lung Neoplasms
2
Leukemia, Myelomonocytic, Chronic
2
Hodgkin Disease
2
Breast Neoplasms
2
Tumor Virus Infections
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Peritoneal Neoplasms
1
Pathologic Complete Response
1
Osteosarcoma
1
Neoplasm Metastasis
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Myeloid Malignancies
1
Melanoma
1
Interventions
sargramostim
2
Monatide (IMS 3015)
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Azacitidine
2
venetoclax
1
ruxolitinib
1
rucaparib
1
olaparib
1
cc-486
1
Pemetrexed
1
Observation
1
Nivolumab
1
Decitabine
1
Cytarabine
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Pathologic Complete Response
×
cc-486
×
Clear all
NCT01757535
2025-07-08
QUAZAR AML-001
Celgene
Phase 3
Completed
472 enrolled
24 charts
1 FDA